PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026Contact Dermatitis0 citations

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

View Full Paper
ZCZohra ChadliKMKhadija MansourGJGhada Jaouahdou

Key Points

  • The aim is to investigate the effectiveness of various testing methods in identifying drug culprits in severe cutaneous adverse drug reactions.
  • Analyzed SCARs at Monastir University Hospital over a 20-year period.
  • Conducted patch tests, intradermal tests, and oral provocation tests.
  • Evaluated cross-reactivity, co-sensitization, and neo-sensitization.
  • Identified 190 SCAR episodes in 188 patients, with DRESS (75%) being the most common.
  • Causative drugs were identified in 97.9% of cases, mainly anti-infectives.
  • Positive rates for PTs in DRESS were 49% and 77% for IDTs; AGEP showed 52% and 66% respectively.
  • Noted cross-reactivity in 7% of DRESS and 11.1% of AGEP cases.
  • Neo-sensitization documented in 32.5% of DRESS patients.

Abstract

ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse drug reactions (SCARs) can be particularly challenging, especially in polymedicated patients. For many years, patch tests (PTs) were considered the only safe and reliable method for investigating SCARs. However, intradermal tests (IDTs), once thought to be contraindicated, have recently garnered increasing interest. Similarly, oral provocation tests, previously avoided due to safety concerns, are now being more frequently employed in SCAR assessment. Methods We analysed SCARs reported at Monastir University Hospital. Allergy work‐up included PTs, IDTs and oral provocation tests, with evaluation of cross‐reactivity, co‐sensitisation and neo‐sensitization. Results We identified 190 SCAR episodes in 188 patients. DRESS was most frequent (75%), followed by AGEP (19%) and SJS/TEN (6%). Causative drugs were identified in 97.9% of cases, mainly anti‐infectives. Skin tests were conducted in 69.5% of patients, yielding positivity rates of 49% for PTs and 77% for IDTs in DRESS, and 52% and 66%, respectively, in AGEP. Cross‐reactivity was noted in 7% of DRESS and 11.1% of AGEP, while neo‐sensitization was documented in 32.5% of DRESS patients. Conclusion Allergological investigations are valuable tools in SCAR management, enabling identification of culprit drugs, assessment of cross‐reactivity, detection of neo‐sensitization and selecting safe alternatives.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chadli et al. (2026) studied this question.

synapsesocial.com/papers/69994cdf873532290d021bd7https://doi.org/10.1111/cod.70118
Ask AI
Helpful
Bookmark
Share
View Full Paper